Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling
Clinical Scorecard: Evaluating the Role of Treatment Accessibility in HIV-TB Co-Infection: A Comparative Approach Using Fractional-Order Modeling
At a Glance
Category Detail
Condition HIV-TB Co-Infection Key Mechanisms HIV-induced immunosuppression increases the risk of TB progression; overlapping toxicities and drug interactions complicate treatment. Target Population Individuals living with HIV, particularly in low- and middle-income countries. Care Setting Resource-constrained healthcare environments.
Key Highlights
HIV-positive individuals are 16–27 times more likely to develop active TB. TB is the leading cause of death among people living with HIV. Integrated approaches combining HIV and TB treatment are essential for effective management. Multidrug-resistant TB (MDR-TB) complicates treatment efforts. Effective management requires addressing healthcare access and stigma. Guideline-Based Recommendations
Diagnosis
Early diagnosis of HIV and TB is critical. Use of robust diagnostic tools to identify co-infection. Management
Integrated treatment strategies for HIV and TB. Scale-up of antiretroviral therapy (ART) and TB preventive therapy. Monitoring & Follow-up
Regular monitoring of treatment adherence and drug interactions. Surveillance data to inform treatment strategies. Risks
Increased mortality risk due to TB among HIV-positive individuals. Potential for drug resistance in TB treatment. Patient & Prescribing Data
Individuals co-infected with HIV and TB, particularly in high-burden regions.
Careful management of ART and anti-TB drugs is necessary to mitigate overlapping toxicities.
Clinical Best Practices
Implement integrated care models for HIV and TB. Enhance healthcare access in low-resource settings. Address stigma to improve treatment adherence. References
